Phaseline

Targets › TROP2

TROP2 (Tumor-associated calcium signal transducer 2): drug programs, companies and trials

22 programs from 17 companies in 92 trials: 35 Phase 2, 35 Phase 1, 22 Phase 3; Oncology, Gastroenterology, Genitourinary; next expected readout Nov 2026.

May function as a growth factor receptor. (UniProt, P09758)

Open in Phaseline: the race on TROP2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sichuan Baili PharmaceuticalBL-B01D1
Anti-TROP2 antibody-drug conjugate
TROP-2, TROP2, TACSTD2Phase 3Nasopharyngeal Carcinoma; Small Cell Lung Cancer; Non-small Cell Lung Cancer; Epithelial Ovarian Cancer …Nov 2026
GSKMocertatug Rezetecan (Mo-Rez)
TROP2-directed antibody-drug conjugate (ADC) with topoisomerase I inhibitor payload
TROP2Phase 3Neoplasms, Endometrial; Ovarian Neoplasms; Tumours, Gynecological; Solid TumorsJun 2027
GSKRisvutatug Rezetecan (GSK5764227)
anti-B7-H3 antibody-drug conjugate
TROP2, CD276Phase 3Neoplasms, Lung; Neoplasms, Prostate; Neoplasms; Gastrointestinal NeoplasmsAug 2027
RenJi Hospital[18F]F-RESCA-RCCB6
Trop2/HER2-targeted PET imaging agent
CD70, TROP2, TACSTD2, ERBB2Phase 2Urologic Neoplasms; Renal Cancer; Solid Tumor; Breast CancerNov 2026
RenJi Hospital[68Ga]Ga-NOTA-R8B4
CD70-targeted immunoPET imaging agent
CD70, TROP2Phase 2Renal Cancer; Solid TumorDec 2026
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityTrop2-ADC
anti-TROP2 antibody-drug conjugate
TROP2Phase 2Metastatic Triple-negative Breast CancerApr 2027
AkesoAK146D1
Anti-Trop2/Nectin4 bispecific antibody-drug conjugate
TROP2, NECTIN4Phase 2Advanced Non Small Cell Lung Cancer (NSCLC); Advanced Breast Cancer; Advanced Solid TumorsMay 2027
Shanghai Chest HospitalSacituzumab Tirumotecan (SKB264)
TROP2-directed antibody-drug conjugate
TROP2Phase 2Esophageal Squamous Cell CarcinomaDec 2027
Fudan UniversityTROP2 ADC
TROP2-targeted antibody-drug conjugate
TROP2Phase 2Triple-negative Breast CancerDec 2027
Shanghai Jiao Tong University School of MedicineSacituzumab Tirumotecan (Sac-TMT)
Anti-TROP2 antibody-drug conjugate (ADC) with SN-38 payload
TROP2Phase 2Breast CancerAug 2028
Bio-Thera SolutionsBAT8008 for Injection
Recombinant humanized anti-Trop2 monoclonal antibody conjugated to exatecan
TROP2Phase 1Advanced Solid TumorsNov 2026
LigaChem BiosciencesLCB84
TROP2-directed antibody-drug conjugate with monomethyl auristatin E (MMAE)
TROP2Phase 1Advanced Solid TumorsJan 2027
Beijing BiotechEB-NK-MF CAR-NK cells
Dual-targeting CAR-NK cells engineered to target Mesothelin and Folate Receptor alpha (wit
MSLN, FOLR1, MUC16, TROP2Phase 1Advanced Solid Tumors; Epithelial Ovarian CancerFeb 2027
Mabwell (Shanghai) Biosciencebulumtatug fuvedotin
anti-TROP2 antibody-drug conjugate
TROP2Phase 1Triple Negative Breast CancerMay 2027
OBI PharmaOBI-992
Anti-TROP2 antibody-drug conjugate with exatecan payload
TROP2Phase 1Advanced Solid TumorJun 2027
M.D. Anderson Cancer CenterTROP2-CAR-NK Cells
TROP2-directed CAR-NK cells with IL-15 transduction
TROP2Phase 1Pancreatic Cancer; Colorectal Cancer; Solid TumorsOct 2027
M.D. Anderson Cancer CenterCytokine-treated Veto Cells
CAR-T/CAR-NK cell therapy targeting IL-13 receptor alpha-1 and EGFvIII on glioblastoma cel
IL13RA1, EGFR, IL21, TGFBR2, NR3C1, TROP2Phase 1Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Phase 1; Colorectal CancerDec 2027
M.D. Anderson Cancer CenterTROP2 CAR/IL-15 TGFBR2 KO NK cells
CAR-T cell therapy targeting TROP2 with IL-15 transduction and TGFBR2 knockout in cord blo
TROP2, IL15, TGFBR2Phase 1Head and Neck CancerDec 2027
Eastern Hepatobiliary Surgery HospitalSuper Hi-TCR-T cells
Multi-target TCR-engineered T cells targeting Nectin4, NKG2DL, TROP2, B7H3, GPC3, and FAP
PVRL4, KLRC1, TROP2, B7H3, GPC3Phase 1Advanced Hepatocellular Carcinoma (HCC)Jan 2028
M.D. Anderson Cancer CenterTGFBR2 KO CAR27/IL-15 NK cells
TROP2-targeted CAR-NK cells with IL-15 co-expression and TGFBR2 knockout
TROP2, TGFBR2, IL15Phase 1Gastric Cancer, Metastatic; LymphoidJul 2028
MacroGenicsvobramitamab tavatecan
anti-TROP2 antibody-drug conjugate with SN-38 payload
TROP2Phase 1Advanced Solid TumorOct 2028
AstellasASP2998
anti-TROP2 antibody-drug conjugate
TROP2Phase 1Locally Advanced or Metastatic Malignant Solid TumorsJun 2029

Conditions

Non-small Cell Lung Cancer (8) Advanced Solid Tumors (6) Breast Cancer (5) Epithelial Ovarian Cancer (3) Esophageal Squamous Cell Carcinoma (3) Urothelial Carcinoma (3) Renal Cancer (3) Ovarian Neoplasms (3) Small Cell Lung Cancer (2) Extensive-stage Small-cell Lung Cancer (2) Triple-negative Breast Cancer (2) Cervical Cancer (2)

Modalities

mixed (10), small molecule (6), antibody (5), other (1)

Companies

M.D. Anderson Cancer Center (4) GSK (2) RenJi Hospital (2) Sichuan Baili Pharmaceutical (1) Astellas (1) Fudan University (1) Shanghai Jiao Tong University School of Medicine (1) Beijing Biotech (1) Akeso (1) MacroGenics (1) OBI Pharma (1) Mabwell (Shanghai) Bioscience (1) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) Shanghai Chest Hospital (1) Eastern Hepatobiliary Surgery Hospital (1) Bio-Thera Solutions (1) LigaChem Biosciences (1)

Related targets

TGFBR2 (3) TACSTD2 (2) IL15 (2) CD70 (2) TROP-2 (1) CD276 (1) MSLN (1) FOLR1 (1) MUC16 (1) ERBB2 (1) NECTIN4 (1) IL13RA1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.